Using low molecular weight heparin in special patient populations

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 2, 2010, Pages 233-240

  Lim, Wendy ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Low molecular weight heparin; Obesity; Pregnancy; Renal insufficiency; Special populations; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN;

ACUTE CORONARY SYNDROME; ANTEPARTUM HEMORRHAGE; BARIATRIC SURGERY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEMATOMA; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; OBESITY; PARTIAL THROMBOPLASTIN TIME; PLASMA PROTEIN BINDING; POSTPARTUM HEMORRHAGE; PREGNANT WOMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; OBESITY; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; RECURRENCE; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 77949918374     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0418-z     Document Type: Conference Paper

References (48)

1. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane. Database. Syst. Rev. 2004, CD001100
2. G Simonneau H Sors B Charbonnier Y Page JP Laaban R Azarian M Laurent JL Hirsch E Ferrari D Mottier B Beau 1997 A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism N Engl J Med 337 663 669 10.1056/NEJM199709043371002 1:CAS:528:DyaK2sXmt1Wqtbg%3D 9278462 (Pubitemid 27375472)
3. DJ Quinlan A McQuillan JW Eikenboom 2004 Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism Ann Intern Med 140 175 183 1:CAS:528:DC%2BD2cXhs1els74%3D 14757615
4. MM Koopman P Prandoni F Piovella PA Ockelford DP Brandjes J van der Meer AS Gallus G Simonneau CH Chesterman MH Prins 1996 Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home N Engl J Med 334 682 687 10.1056/NEJM199603143341102 1:STN:280: DyaK287nsFWlsQ%3D%3D 8594426 (Pubitemid 26079801)
5. IG Schraibman AA Milne EM Royle 2001 Home versus in-patient treatment for deep vein thrombosis Nurs Times 97 35 1:STN:280:DC%2BD383ivVGmsw%3D%3D 11966120
6. MN Levine A Planes J Hirsh M Goodyear N Vochelle M Gent 1989 The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement Thromb Haemost 62 940 944 1:STN:280: DyaK3c%2FosFWltA%3D%3D 2556813
7. HK Nieuwenhuis J Albada JD Banga JJ Sixma 1991 Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin Blood 78 2337 2343 1:STN:280: DyaK38%2Fjt1yqtQ%3D%3D 1657248
8. L Bara A Leizorovicz H Picolet M Samama 1992 Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin study group Thromb Res 65 641 650 10.1016/0049-3848(92)90213-T 1:STN:280:DyaK38zhtFykug%3D%3D 1319619
9. P Prandoni AW Lensing HR Buller M Carta A Cogo M Vigo D Casara A Ruol JW ten Cate 1992 Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis Lancet 339 441 445 10.1016/0140-6736(92)91054-C 1:STN:280:DyaK387lslKqtA%3D%3D 1346817
10. JM Walenga D Hoppensteadt J Fareed 1991 Laboratory monitoring of the clinical effects of low molecular weight heparins Thromb Res Suppl 14 49 62 10.1016/0049-3848(91)90403-J 1:STN:280:DyaK38%2FlsFCqug%3D%3D 1658970
11. J Hirsh KA Bauer MB Donati M Gould MM Samama JI Weitz 2008 Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edn) Chest 133 141S 159S 10.1378/chest.08-0689 1:CAS:528:DC%2BD1cXptVKiu7w%3D 18574264
12. Kidney Disease Outcome Quality Initiative (2002) K/DOQI clinical practice guidelines for chronic renal disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1-S46
13. W Lim F Dentali JW Eikelboom MA Crowther 2006 Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency Ann Intern Med 144 673 684 1:CAS:528:DC%2BD28Xlt1artbg%3D 16670137
14. CS Landefeld RJ Beyth 1993 Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention Am J Med 95 315 328 10.1016/0002-9343(93)90285-W 1:STN:280:DyaK3sznslKruw%3D%3D 8368229
15. J Douketis D Cook M Meade G Guyatt W Geerts Y Skrobik M Albert J Granton P Hebert G Pagliarello J Marshall R Fowler A Freitag C Rabbat D Anderson N Zytaruk D Heels-Ansdell M Crowther 2008 Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and pharmacodynamics: the DIRECT study Arch Intern Med 168 1805 1812 10.1001/archinte.168.16.1805 1:CAS:528:DC%2BD1cXhtFOjtrrJ 18779469
16. I Mahe M Aghassarian L Drouet CB Dit-Sollier K Lacut JJ Heilmann D Mottier JF Bergmann 2007 Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study Thromb Haemost 97 581 586 1:CAS:528: DC%2BD2sXks1Onuro%3D 17393021
17. E Tincani C Mannucci B Casolari F Turrini MA Crowther D Prisco AM Cenci M Bondi 2006 Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study Haematologica 91 976 979 1:CAS:528:DC%2BD28XnslSms7w%3D 16757417
18. C Falga JA Capdevila S Soler R Rabunal JF Sanchez Munoz-Torrero P Gallego M Monreal 2007 Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry Thromb Haemost 98 771 776 1:CAS:528:DC%2BD2sXht12ju77M 17938800
19. JJ Santopinto KA Fox RJ Goldberg A Budaj G Pinero A Avezum D Gulba J Esteban JM Gore J Johnson EP Gurfinkel 2003 Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE) Heart 89 1003 1008 10.1136/heart.89.9.1003 1:CAS:528:DC%2BD3sXns1Citbg%3D 12923009
20. Collet JP, Montalescot G, Agnelli G, Van de WF, Gurfinkel EP, Lopez-Sendon J, Laufenberg CV, Klutman M, Gowda N, Gulba D (2005) Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The global registry of acute coronary events. Eur Heart J 26:2285-2293
21. SA Spinler SM Inverso M Cohen SG Goodman KA Stringer EM Antimann 2003 Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies Am Heart J 146 33 41 10.1016/S0002-8703(03)00121-2 1:CAS:528:DC%2BD3sXltF2ju7o%3D 12851605 (Pubitemid 36851297)
22. Spinler SA, Mahaffey KW, Gallup D, Levine GN, Ferguson JJ III, Rao SV, Gallo R, Ducas J, Goodman SG, Antman E, White HD, Biasucci L, Becker RC, Col JJ, Cohen M, Harrington RA, Califf RM (2009) Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol 2009 [Epub ahead of print]
23. V Siguret E Pautas M Fevrier C Wipff B Durand-Gasselin M Laurent JP Andreux M d'Urso P Gaussem 2000 Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days Thromb Haemost 84 800 804 1:CAS:528:DC%2BD3cXovFCjsL8%3D 11127859
24. E Pautas I Gouin O Bellot J-P Andreux V Siguret 2002 Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients Drug Saf 25 725 733 10.2165/00002018-200225100-00005 1:CAS:528:DC%2BD38Xntl2jsrw%3D 12167068
25. Aventis Pharma Inc. (2004) Lovenox product monograph (enoxaparin sodium). Ref Type: Pamphlet
26. KA Fox EM Antman G Montalescot S Agewall B SomaRaju FW Verheugt J Lopez-Sendon H Hod SA Murphy E Braunwald 2007 The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial J Am Coll Cardiol 49 2249 2255 10.1016/j.jacc.2006.12.049 1:CAS:528:DC%2BD2sXmtlWisrc%3D 17560289 (Pubitemid 46863477)
27. T Lachish B Rudensky I Slotki S Zevin 2007 Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety Pharmacotherapy 27 1347 1352 10.1592/phco.27.10.1347 1:CAS:528: DC%2BD2sXht1aks77M 17896889 (Pubitemid 47530440)
28. SJ Wilson K Wilbur E Burton DR Anderson 2001 Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism Haemostasis 31 42 48 1:CAS:528:DC%2BD3MXlslSksr0%3D 11408748
29. GJ Sanderink A Le Liboux N Jariwala N Harding ML Ozoux U Shukla G Montay B Boutouyrie A Miro 2002 The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers Clin Pharmacol Ther 72 308 318 10.1067/mcp.2002.127114 1:CAS:528:DC%2BD38XotVSmurg%3D 12235452
30. JW Hainer JS Barrett CA Assaid MJ Fossler DS Cox T Leathers PT Leese 2002 Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study Thromb Haemost 87 817 823 1:CAS:528:DC%2BD38Xkt1Smtb4%3D 12038783
31. A Bazinet K Almanric C Brunet I Turcotte J Martineau S Caron N Blais L Lalonde 2005 Dosage of enoxaparin among obese and renal impairment patients Thromb Res 116 41 50 10.1016/j.thromres.2004.10.004 1:CAS:528: DC%2BD2MXjsVGlur8%3D 15850607 (Pubitemid 40546324)
32. E Al Yaseen PS Wells J Anderson J Martin MJ Kovacs 2005 The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients J Thromb Haemost 3 100 102 10.1111/j.1538-7836.2004.01053.x 1:CAS:528:DC%2BD2MXht12rtLo%3D 15634272 (Pubitemid 41647121)
33. R Barba J Marco H Martin-Alvarez P Rondon C Fernandez-Capitan F Garcia-Bragado M Monreal 2005 The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE) J Thromb Haemost 3 856 862 10.1111/j.1538-7836.2005.01304.x 1:STN:280:DC%2BD2M3jsFKjtA%3D%3D 15869577 (Pubitemid 41632810)
34. Mahaffey KW, Tonev ST, Spinler SA, Levine GN, Gallo R, Ducas J, Goodman SG, Antman EM, Becker RC, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ, Califf RM (2008) Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial. Int J Cardiol
35. R Alikhan AT Cohen S Combe MM Samama L Desjardins A Eldor C Janbon A Leizorovicz CG Olsson AG Turpie 2003 Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study Blood Coagul Fibrinolysis 14 341 346 10.1097/00001721-200306000-00004 1:CAS:528:DC%2BD3sXltlejurg%3D 12945875 (Pubitemid 36688187)
36. N Kucher A Leizorovicz PT Vaitkus AT Cohen AG Turpie CG Olsson SZ Goldhaber 2005 Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial Arch Intern Med 165 341 345 10.1001/archinte.165. 3.341 1:CAS:528:DC%2BD2MXitVGntb8%3D 15710801 (Pubitemid 40216291)
37. WH Geerts D Bergqvist GF Pineo JA Heit CM Samama MR Lassen CW Colwell 2008 Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edn) Chest 133 381S 453S 10.1378/chest.08-0656 1:CAS:528:DC%2BD1cXptVKhsrg%3D 18574271
38. EE Mason S Tang KE Renquist DT Barnes JJ Cullen C Doherty JW Maher 1997 A decade of change in obesity surgery. National bariatric surgery registry (NBSR) contributors Obes Surg 7 189 197 10.1381/096089297765555719 1:STN:280:DyaK1czpvVeitw%3D%3D 9730547 (Pubitemid 27289344)
39. RH White H Zhou PS Romano 2003 Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures Thromb Haemost 90 446 455 1:CAS:528:DC%2BD3sXnsFKgtbo%3D 12958614
40. DJ Scholten RM Hoedema SE Scholten 2002 A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery Obes Surg 12 19 24 10.1381/096089202321144522 11868291 (Pubitemid 34155256)
41. MJ Borkgren-Okonek RW Hart JE Pantano PC Rantis Jr PJ Guske JM Kane Jr N Gordon NC Sambol 2008 Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity Surg Obes Relat Dis 4 625 631 10.1016/j.soard.2007.11.010 18261965
42. I Raftopoulos C Martindale A Cronin J Steinberg 2008 The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial Surg Endosc 22 2384 2391 10.1007/s00464-008-0031-9 18622558
43. SM Bates IA Greer I Pabinger S Sofaer J Hirsh 2008 Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American college of chest physicians evidence-based clinical practice guidelines (8th edn) Chest 133 844S 886S 10.1378/chest.08-0761 1:CAS:528:DC%2BD1cXptVKhsL0%3D 18574280
44. AJ Carlin RG Farquharson SM Quenby J Topping WD Fraser 2004 Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control Hum Reprod 19 1211 1214 10.1093/humrep/deh115 1:CAS:528:DC%2BD2cXjs1WrsL0%3D 15121733 (Pubitemid 38618507)
45. IA Greer C Nelson-Piercy 2005 Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy Blood 106 401 407 10.1182/blood-2005- 02-0626 1:CAS:528:DC%2BD2MXmtleqs7c%3D 15811953 (Pubitemid 40981229)
46. LA Barbour JM Smith RA Marlar 1995 Heparin levels to guide thromboembolism prophylaxis during pregnancy Am J Obstet Gynecol 173 1869 1873 10.1016/0002-9378(95)90443-3 1:CAS:528:DyaK28XptlSntA%3D%3D 8610778 (Pubitemid 26005777)
47. AF Jacobsen E Qvigstad PM Sandset 2003 Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy BJOG 110 139 144 10.1046/j.1471-0528.2003.02182.x 1:CAS:528:DC%2BD3sXhs1WntLY%3D 12618157 (Pubitemid 36263109)
48. VA Rodie AJ Thomson FM Stewart AJ Quinn ID Walker IA Greer 2002 Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series BJOG 109 1020 1024 10.1111/j.1471-0528.2002.01525.x 1:CAS:528:DC%2BD38Xms1Grtr8%3D 12269676